New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
07:20 EDTONTYOncothyreon price target lowered to $4 from $11 at Cantor
Cantor reduced its price target on Oncothyreon as the firm believes that the company's Stimuvax drug is no longer a commercial candidate. However, the firm believes that Oncothyreon's cancer treatment PX-866, along with its cash, could be worth about $3.90 per share. The firm maintains a Buy rating on the stock.
News For ONTY From The Last 14 Days
Check below for free stories on ONTY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:50 EDTONTYOncothyreon raises $40M in common stock and preferred stock offerings
Subscribe for More Information
September 17, 2014
18:29 EDTONTYOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTONTYOncothyreon fiels to sell common stock and convertible preferred stock
Oncothyreon announced that it intends to offer and sell shares of its Common Stock and Series A Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series A Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. Cowen and Company, LLC is acting as the sole book-running manager in the offerings.
September 12, 2014
09:14 EDTONTYOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTONTYOncothyreon says Merck KGaA discontinues development of tecemotide in NSCLC
Oncothyreon (ONTY) disclosed earlier in a regulatory filing that Merck KGaA (MKGAY), which has world-wide rights for the development and commercialization of tecemotide under a license agreement with Oncothyreon, announced that its biopharmaceutical division will discontinue the clinical development program of the investigational MUC1 antigen-specific cancer immunotherapy as a monotherapy in Stage III non-small cell lung cancer, or NSCLC. The decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients. Merck Serono has made the decision to discontinue all other Merck Serono-sponsored clinical trials with tecemotide in NSCLC worldwide. Those patients on active treatment with tecemotide can undergo an individual assessment by their treating physician and apply to receive further treatment outside of the studies. Merck Serono will continue to supply tecemotide for ongoing investigator-sponsored trials in other indications in accordance with their agreements with the sponsors of these studies. Shares of Oncothyreon are down 12% in pre-market trading following the news from its partner.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use